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Objective: Aprotinin reduces postoperative bleeding and the need for 
transfusion after cardiopulmonary bypass. The current clinical concern 
about aprotinin is that it may increase the incidence of postoperative graft 
thrombosis and thromboembolic phenomena. The fact that the mechanism 
of action of aprotinin is still not completely elucidated and that its effects 
on the vascular eactivity of bypass conduits are unknown raise doubts 
regarding its safety. In an attempt to clarify these issues we investigated the 
vascular reactivity of the human saphenous vein and internal thoracic 
artery to a range of vasoconstrictor agents in the presence or absence of 
aprotinin. Methods: Human saphenous vein was obtained from 24 patients 
and internal thoracic artery from 7 patients undergoing coronary artery 
bypass. Vessels were set up in organ baths to record changes in vessel wall 
tension. Results: Endothelium-dependent relaxations to acetylcholine in 
saphenous vein rings were unaffected after aprotinin treatment. Contrac- 
tions to the thromboxane analog U46619 were significantly attenuated after 
aprotinin treatment in the saphenous vein. Maximum responses were 
reduced from control values of 88 - 7.5 mN to 49.3 - 4.8 mN with 1/zmol/L 
doses of aprotinin (p < 0.05) and 36.6 - 4.8 mN with 10 ~mo!/L doses of 
aprotinin (p < 0.05). There was no attenuation of contractions induced by 
5-hyroxytryptamine or noradrenaline after aprotinin incubations. Further- 
more, contractions to U46619 in the internal thoracic artery were unaf- 
fected by aprotinin. Conclusion: Our data show that there is a preservation 
of endothelium-dependent responses to acetylcholine and a reduced 
U46619 vasoconstrictor action on the saphenous vein after aprotinin 
treatment. Thus the direct effect of aprotinin on the vessel wall could 
counteract the potential effect of its prothrombotic action on graft patency. 
(J Thorac Cardiovasc Surg 1997;113:319-26) 
T he nonspecific serine protease inhibitor aprotinin reduces postoperative bleeding and the need for 
transfusion after cardiopulmonary bypass. 1-3 The 
mechanism of action of aprotinin is still unknown. It 
is, however, recognized that aprotinin can act to 
inhibit plasmin 2and other factors in the coagulation 
cascade. In addition, there is evidence to suggest 
that aprotinin can inhibit certain control proteases 
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in coagulation and fibrinolysis, in particular, acti- 
vated protein C and tissue plasminogen activator. 4 
Aprotinin may also improve hemostasis by preserv- 
ing the components of platelet adhesion, 5' 6 which 
are otherwise damaged uring the initial phase of 
cardiopulmonary b pass. 7 Platelet adhesion and ac- 
tivation during bypass can result in production of a 
variety of mediators including 5-hydroxytryptamine 
(5-HT) and thromboxane A 2 (TXA2), which are 
known to affect endothelial and smooth muscle cell 
function. Because the regulated release of platelet 
stimulators and inhibitors by endothelial cells is 
essential to the control of platelet adhesion and 
activation, s it is possible that aprotinin could directly 
influence vascular eactivity and graft performance 
by enhancing platelet stimulation or by the interac- 
tion of platelets with the vessel wall, or both. Fur- 
thermore, the response of smooth muscle cells to 
vasoactive mediators released from activated plate- 
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Fig. 1. Effect of aprotinin concentration on endothelium-dependent r laxations to acetylcholine in the 
human saphenous vein (1 nmol/L to 10/xmol/L; n = 6). 
lets could also be a target for the actions of aproti- 
nin. 
Although the practical use of aprotinin for pa- 
tients undergoing cardiopulmonary b pass has been 
widely endorsed because of its hemostasis-preserv- 
ing effect, clinical reports have questioned the over- 
all safety of aprotinin therapy, v'10 The current con- 
cern about aprotinin is that it may have an overall 
prothrombotic effect, thus increasing the incidence 
of postoperative graft thrombosis and thromboem- 
bolic phenomena. Although controlled clinical stud- 
ies have failed to show or confirm these problems 
the fact that the mechanism of action of aprotinin is 
still not completely elucidated and that its effects on 
the vascular eactivity of bypass conduits unknown 
raise doubts regarding its safety. In an attempt o 
clarify these issues we investigated the reactivity of 
the human saphenous vein and internal thoracic 
artery (ITA) to the endothelium-dependent vasodi- 
lator acetylcholine and to a range of vasoconstrictor 
agents released from platelets or administered 
perioperatively in the presence or absence of apro- 
tinin. 
Material and methods 
Tissue preparation. Specimens of human undistended 
saphenous vein from 24 patients and ITA from 7 patients 
were obtained as excess to requirements during coronary 
artery bypass operations. Informed consent was obtained 
from each patient and the study was approved by the 
Harefield Hospital ethical committee. No patient incor- 
porated in the study was receiving aprotinin periopera- 
tively. Vessels were immediately placed in modified Ty- 
rode's olution of the following composition (in millimoles 
per liter): NaCl 136.9; NaHCO 3 11.9; KC1 2.7; NaH2PO 4 
0.4; MgC1 2.5; CaC12 2.5; glucose 11.1; and disodium 
ethylenediaminetetraacetic acid 0.04. The blood vessels 
were then dissected free from connective tissue under a 
light microscope. Rings of saphenous vein and ITA were 
then mounted for isometric tension recording in organ 
baths filled with modified Tyrode's olution aerated with a 
95% oxygen and 5% carbon dioxide mixture. The temper- 
ature of the organ baths was maintained at 37 ° C. 
Experimental protocol. Before each experiment, sa- 
phenous vein ring segments were stretched to an initial 
tension of 6 gm and the ITAs were stretched to 4 gin. 
These preloads have been shown to be optimal for the 
maximal isometric ontraction i response to a 90 mmol/L 
dose Of potassium chloride. The segments were allowed to 
relax for a period of 60 minutes. When resting tension was 
stable each ring was challenged with a 90 mmol/L dose of 
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Fig. 2. Effect of aprotinin concentration on smooth muscle vasoconstriction to U46619 in the human 
saphenous vein (0.1 nmol/L to 1/xmol/L). Contractions to U46619 were significantly attenuated (p < 0.05; 
n = 6) at both 1 txmol/L and 10 tzmol/L doses of aprotinin. 
Tab le  I. Effect o f  aprotinin concentration on potency o f  acetylcholine, U46619, 5-HT, and noradrenaline in 
the human saphenous vein and of  U46619 in the ITA 
pD 2 values by aprotinin dose 
3 × 10 7 mol/L 10 .6 mol/L 3 × 10 .6 mol/L 10 5 mol/L Control 
U46619 (SV) 8.3 -+ 0.3 8.i ± 0.2 8.2 -+ 0.3 8.2 -+ 0.2 8.3 +- 0.3 
NAD (SV) 7.4 -+ 0.2 7.2 + 0.2 7.1 -+ 0.1 7.2 -+ 0.1 7.0 +- 0.1 
5-HT (SV) 7.2 -+ 0.2 7.1 ± 0.2 7.0 -- 0.1 7.3 +- 0.3 7.0 ± 0.2 
Ach (SV) 7.8 ± 0.2 6.4 + 0.4 NC 7.2 +- 0.5 7.1 ± 0.2 
U46619 (ITA) NC 8.6 -+ 0.2 NC 8.8 -+ 0.1 8.3 -+ 0.4 
sv, Saphenous vein; NAD, noradrenaline; Ach, acetylcholine; NC, not calculated. 
potassium chloride (the bath solution was changed be- 
tween doses 'when the responses reached a plateau) to 
verify the reactivity of the vessel. Vessels in which the KC1 
response was less than 10 mN were discarded to reduce 
the inherent differences in reactivity observed between 
patients. After two potassium chloride responses were 
obtained, the vessel segments were washed and allowed to 
reequilibrate for 30 minutes. After this period ring seg- 
ments were incubated for 1 hour with a range of aprotinin 
concentrations that are normally used clinically under our 
high-dose regimen (0.3 /xmol/L to 10 txmol/L). 11 At the 
end of the incubation period the rings were assessed with 
respect to their ability to vasodilate or vasoconstrict in 
response to a range of vasoactive mediators still in the 
presence of aprotinin. Only one drug was assessed in each 
vessel segment. 
Endothelial function. To assess the effect of aprotinin 
on endothelial function in the saphenous vein, ring seg- 
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Fig. 3. Effect of aprotinin concentration on smooth muscle vasoconstriction to noradrenaline in the 
human saphenous vein (1 nmol/L to 10 tzmol/L; n = 6). 
ments were preconstricted with the TXA 2 analog U46619 
(1 nmol/L) by adding the drug to the Tyrode's solution 
bath. Once a stable plateau was reached, cumulative 
additions of the endothelium-dependent vasodilator ace- 
tylcholine (1 nmol/L to 1 /,mol/L) were made in the 
presence and absence of aprotinin. 
Smooth muscle cell function. To assess the effect of 
aprotinin on vascular smooth muscle cell function, vessel 
segments were challenged with either 5-HT, U46619, or 
noradrenaline by addition of increasing concentrations of 
each agonist o the baths in a cumulative manner. 
Analysis of data. The relaxations were expressed as 
percentage decrease in tension of the contraction in- 
duced by U46619. Contractions were measured as 
absolute tension in grams. For analysis of the responses 
the concentration of agonist exhibiting 50% of the 
maximum response (EC50) was calculated. EC50 values 
for each concentration-response curve were obtained by 
a probit transformation of the data points to linearize 
the sigmoidal curves. Linear-regression a alysis of data 
points versus log concentration above and below the 
50% response level was then obtained. The values were 
transformed into geometric means (pD2 values), which 
were approximately normally distributed following 
analysis of frequency of values over a range of standard 
deviation units from the mean. The efficacy of the 
saphenous vein and ITA to all agonists was represented 
by the maximum contractile response. All results are 
shown as means plus or minus the standard error of the 
mean where n equals the number of patients from 
whom the vessels were obtained. Statistical analysis was 
done by a repeated-measures analysis of variance fol- 
lowed by paired t tests with Bonferroni's correction for 
multiple comparisons (Primer Biostatistics, Stanton A. 
Glantz) on each ring segment o address dependencies 
between observations in the same tissue and tissues 
from the same person. In each case the same number of 
tissue rings per agonist was used from each patient to 
look at differences between treatments at different 
doses of constrictor. Two-sided values ofp  < 0.05 were 
considered to be statistically significant. 
Results 
Effect of aprotinin on endothelial function. En- 
dothe l ium-dependent  relaxations to acetylchol ine in
saphenous vein ring segments after incubation with 
aprot inin were unaffected in relat ion to control  
responses (Fig. 1; n = 6). There was no significant 
difference in U46619 constrict ions used for provid- 
ing a pretension for acetylcholine relaxations be- 
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Fig. 4. Effect of aprotinin concentration on smooth muscle vasoconstriction to 5-HT in the human 
saphenous vein (1 nmol/L to 10 ~mol/L; n = 6). 
tween control and aprotinin-treated segments. Also, 
comparison of the sensitivity (pD2) of acetylcholine 
between control and aprotinin groups showed a 
maximum log shift of approximately onefold (7.1 vs 
7.8 and 7.1 vs 6.4, respectively), which was statisti- 
cally nonsignificant (Table I). 
Effect of aprotinin on vascular smooth muscle cell 
function. Additions of the TXA 2 analog U46619, 
noradrenaline, and 5-HT all produced concentra- 
t ion-dependent contractions of saphenous vein 
segments. In all cases the responses of the tissues 
to each agonist were similar for each patient with 
no evidence of large variations in reactivity, which 
could bias the results. Furthermore, when the 
results were expressed as a percentage of the 
response to KC1 (to normalize for differences in 
tissue reactivity) there was no difference in the 
responses to each constrictor (data not shown). 
Therefore ',all the tissue rings from the different 
patients were averaged among all the various 
treatments. The responses to U46619 were atten- 
uated after incubations with aprotinin (Fig. 2; n = 
6). The maximum responses were reduced from a 
control value of 88 + 7.5 mN to 49.3 __ 4.8 mN 
with a 1 /xmol/L dose of aprotinin (p < 0.05, n = 
6) and to 36.6 + 5.4 mN with a 10/xmol/L dose of 
aprotinin (p < 0.05, n = 6). The contractile 
responses to noradrenaline in the presence of 
aprotinin were also depressed, although this did 
not reach statistical significance (Fig. 3; p = 0.3, 
n = 6). Similarly, contractions induced by 5-HT 
were attenuated in the presence of aprotinin but 
this was also not significant (Fig. 4; p = 0.3, n = 
6). 
In contrast to findings in the saphenous vein, 
contractions to U46619 were unaffected by aprotinin 
treatment in the ITA (control value 37.8 + 5.1 mN 
versus 37.2 _+ 6.0 mN with a 1 /xmol/L dose of 
50- 
Allen et aL 
The Journal of Thoracic and 
Cardiovascular Surgery 
February 1997 
40-  
om 20-  
Imal 
10- 
0 
-1 
! I 
-10 -9 
324 
| | I I 
-8 -7 -6 -5 
-- Control 
~. 1 p~l Aprotinin 
: 10 ~ Aprotinin 
U46619 (log M) 
Fig. 5. Effect of aprotinin concentration smooth muscle vasoconstriction to U46619 in the human ITA 
(0.1 nmol/L to 1 txmol/L; n = 6). 
aprotinin [p = 0.2, n = 7] and versus 31.3 _+ 3.9 mN 
with a 10/xmol/L dose of aprotinin [p = 0.2, n = 7]) 
(Fig. 5). In addition, there was no significant differ- 
ence in pD2 values between control and aprotinin- 
treated vessels in response to U46619, noradrena- 
line, or 5-HT in either the vein or artery (Table I). 
Discussion 
This study showed that exposure of human coro- 
nary bypass grafts to aprotinin, in a clinically rele- 
vant dose range, attenuated the U46619-induced 
smooth muscle cell vasoconstriction i  the saphe- 
nous vein but not in the ITA. Furthermore, aproti- 
nin did not affect endothelium-dependent relax- 
ations to acetylcholine in the saphenous vein. 
High-dose aprotinin is being used with increasing 
frequency to reduce perioperative blood loss during 
cardiac operations with the use of cardiopulmonary 
bypass. Aprotinin is a basic polypeptide that inhibits 
serine proteases: it inhibits a wide range of serine 
proteases from plasmin to kallikrein to trypsin and 
chymotrypsin. 12 Excessive kallikrein is formed from 
its precursor prekallikrein during cardiopulmonary 
bypass, during activation of factor XII by the artifi- 
cial surface of the bypass equipment, and by the 
exposed subendothelial tissues of the surgically cut 
vessels. 13 Together with the antiplasmin effect of 
aprotinin, inhibition of kallikrein has a powerful 
antifibrinolytic effect by indirectly limiting the for- 
mation of activators of plasminogen. 4 Aprotinin is 
also known to have a preservative effect on platelet 
function that seems to be important in its ability to 
reduce blood loss. 5' 6, 14 
Vascular endothelium plays an important part in 
the control of the coagulation pathway and the 
limitation and localization of the dotting process. 
An important substance released from the endothe- 
lium that is involved in the modulation of hemosta- 
sis and thrombosis is endothelium-derived nitric 
oxide. Nitric oxide can inhibit the adherence of 
platelets to endothelial cells. 15' 16 A reduction in the 
release of nitric oxide would increase adherence of 
platelets to endothelial cells, favoring the formation 
of a platelet plug and therefore arresting bleeding. 
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The present data show no evidence of a reduction in 
acetylcholine-stimulated nitric oxide release in sa- 
phenous veins, which suggests that aprotinin does 
not interfere with endothelial function. It is also 
highly unlikely that aprotinin is masking an attenu- 
ating effect on acetylcholine-induced relaxations by 
attenuating the U46619 preconstriction inasmuch as 
(1) there was no significant difference in the precon- 
striction between control and aprotinin-treated tis-
sue and (2) as shown in Fig. 2 there was no 
difference in the degree of constriction with U46619 
(1 nmol/L) between control and aprotinin-treated 
tissues. Finally, although acetylcholine is known to 
produce vasoconstriction f vascular smooth muscle 
at high concentrations, this was never seen in the 
concentration range used in our relaxation experi- 
ments. Whether acetylcholine relaxations would 
have been altered in ITAs was not examined in this 
study because of the limited availability of tissue. It 
may be argued that smaller diameter arteries are 
more prone to clinically relevant vasoconstriction 
than veins. However, ITAs are known to produce 
greater elaxations than veins. This, together with 
our present results in the saphenous vein, would 
argue against an attenuation of relaxations caused 
by aprotinin. Previous tudies have shown that apro- 
tinin does not inhibit release of prostacyclin or von 
Willebrand's factor from cultured human endothe- 
lial cells. 17 This could have important clinical impli- 
cations because nitric oxide and prostacyclin act 
synergistically in providing a mechanism to protect 
from spasm and inhibit platelet aggregation and 
smooth muscle cell proliferation. 
A novel finding in the present study was that 
aprotinin attenuated the powerful vasoconstrictor 
action of U46619 in the saphenous vein. This effect 
appeared to be site specific because no attenuation 
of U46619 responses in the ITA were reported after 
aprotinin treatment. I  seems unlikely that this effect 
was a result of some chemical interaction of aproti- 
nin with U46619 because there was no effect on 
contractions in the artery. It also appears that the 
effect is specific to the TXA 2 receptor pathway 
because no significant differences in responses to 
5-HT or noradrenaline were found, although a 
nonspecific effect of aprotinin cannot be ruled out if 
a greater number of experiments were to be per- 
formed. The ability of aprotinin to influence TXA 2 
is further supported by the finding that TXA 2 levels 
after cardiopulmonary b pass are reduced in pa- 
tients given aprotinin treatment. 1-3The mechanism 
or mechanisms responsible for this effect are not 
known, but could help in clarifying the mechanism 
of the ability of aprotinin to arrest bleeding and the 
overall safety of its therapy. After vascular injury the 
arrest of bleeding is controlled by (1) local vasocon- 
striction, (2) formation of a platelet plug, and (3) 
clot formation. It is also possible that by reducing 
the local powerful TXA 2 contractions, aprotinin 
could aid platelet adhesion by reducing the forces 
generated at the site of inflammation by increasing 
vasomotor stability and thus contribute to stabilizing 
the platelet plug. 
It has been suggested that aprotinin may cause 
premature saphenous vein graft occlusion. 9'10 The 
evidence of vein graft hrombosis raises the question 
of a hypercoagulable state that may adversely influ- 
ence patient outcome. Our data suggest hat the 
preservation ofendothelial cell nitric oxide function 
together with the reduced vasoconstrictor action of 
the saphenous vein with U46619 in the presence of 
aprotinin could reduce the chances of vein graft 
thrombosis by favoring antithrombotic aspects of 
vessel wall function. 
The major limitation of this study is that the 
effects of aprotinin were examined in a blood-free 
system. Because aprotinin has several interactions 
with blood components that could influence its 
overall effect on blood vessel physiologic processes, 
our results with use of an organ bath system, which 
used physiologic Tyrode's solution to bathe the 
vessels, would need to be confirmed in a blood- 
perfused vessel to further confirm the ability of 
aprotinin to affect vascular eactivity. 
In conclusion, aprotinin preserved endothelial 
function and counteracted the potent contractions 
of U46619 in the saphenous vein. These findings 
could help in the understanding of the mechanisms 
of action of aprotinin and have important clinical 
implications with regard to the possible ffect of the 
drug in bypass graft function. 
REFERENCES 
1. Van Oeveren W, Jansen NJG, Bidstrup BP, et al. Effects of 
aprotinin on hemostatic mechanisms during cardiopulmo- 
nary bypass. Ann Thorac Surg 1987;44:640-5. 
2. Bidstrup BP, Royston D, Sapsford RN, Taylor KM. Reduc- 
tion in blood loss and blood use after cardioputmonary 
bypass with high dose aprotinin. J Thorac Cardiovasc Surg 
1989;97:364-72. 
3. Blauhut B, Gross C, Necek S, Doran JE, Spath P, Lunds- 
gaard~Hartsen P. Effects of high-dose aprotinin on blood 
loss, platelet function, fibrinolysis, complement, and renal 
function after cardiopulmonary bypass. J Thorac Cardiovasc 
Surg 1991;101:958-67. 
3 2 6 Allen et al. 
The Journal of Thoracic and 
Cardiovascular Surgery 
February 1997 
4. Hunt B J, Yacoub M. Aprotinin and cardiac surgery [Edito- 
rial]. BMJ 1991;303:660-1. 
5. Kallis P, Tooze JA, Talbot S, Cowarts D, Bevan DH, Treasure 
T. Aprotinin inhibits fibrinolysis, improves platelet adhesion and 
reduces blood loss. Eur J Cardiothorac Surg 1994;8:315-23. 
6. Tabuchi N, De Haan J, Boonstra PW, Gallandat Huet RCG, 
Van Oeveren W. Aprotinin effect on platelet and clotting 
during cardiopulmonary b pass. Eur J Cardiothorac Surg 
1994;8:87-90. 
7. Van Oeveren W, Eijsman L, Roozendaal KJ, Wildevuur 
CRH. Platelet preservation by aprotinin during cardioputmo- 
nary bypass. Lancet 1988;1586:644. 
8. Nievelstein PFEM, de Groot PG. Interaction of blood plate- 
lets with the vessel wall. Haemostasis 1988;37:89-91. 
9. Cosgrove DM III, Heric B, Lytle BW, et al. Aprotinin 
therapy for reoperative myocardial revascularization: place- 
bo-controlled study. Ann Thorac Surg 1992;54:1031-8. 
10. Sundt TIII, Kouchoukos NT, Saffitz JE, Murphy SF, Ware- 
ing TH, Stahl JS. Renal dysfunction and intravascular coag- 
ulation with aprotinin and hypothermic irculatory arrest. 
Ann Thorac Surg 1993;55:659-61. 
11. Royston D, Bidstrup BP, Taylor KM, Sapsford RN, Effect of 
aprotinin on the need for blood transfusion after repeat open 
heart surgery. Lancet 1987;(ii):1289-91. 
12. Fritz H, Wunder G, Biochemistry and applications of apro- 
tinin, the kallikrein inhibitor. Drug Res 1983;33:474-94. 
13. Tanaka K, Takao M, Yada I, Yuasa H, Kusagawa M, 
Deguchi K. Alterations in coagulation and fibrinolysis asso- 
ciated with cardiopulmonary b pass during open-heart sur- 
gery. J Cardiothorac Vasc Anesth 1989;3:181-8. 
14. Van Oeversen W, Harder MP, Roozendaal KJ, Eijsman L, 
Wildervuur CRH. Aprotinin protects platelets against he 
initial effects of cardiopulmonary b pass. J Thorac Cardio- 
vasc Surg 1990;99:788-99. 
15. Radomski MW, Palmer RMJ, Moncada S. The role of nitric 
oxide and cGMP in platelet adhesion to vascular endothe- 
lium. Biochem Biophys Res Commun 1987;148:1482-9. 
16. Sneddon JM, Vane JR. Endothelium-derived r laxing factor 
reduces platelet adhesion to bovine endothelial cells. Proc 
Natl Acad Sci 1988;85:2800-4. 
17. Royston BD, Royston D, Coade SB, Morgan DML, Pearson 
JD. Aprotinin does not inhibit the release of PGIz or vWF 
from cultured human endothelial cells. Thromb Haemost 
1992;67:172-5. 
